Scientific Computing Research Unit (SCRU) have uncovered a critical molecular “switch” that drives the formation of cancer-associated antigens. The study, published in Nature Communications, details ...
Epitopea also announces the appointment of Professor Susana Banerjee (MBBS MA PhD FRCP), a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of ...
University of Cape Town researchers have identified how enzyme relocation inside cells triggers the formation of ...
Epitopea has received approval from the UK’s Medicines and Healthcare products Regulatory Agency and the Regional Ethics ...
Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line ...
A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...
Researchers at Memorial Sloan Kettering Cancer Center and the University of Cape Town have uncovered early cellular changes and molecular switches that drive tumor growth. These discoveries, involving ...
• This study aimed to investigate the immunophenotype of esophageal cancer (ESCA) by assessing the patient’s immune defenses or autoimmune function and to identify potential tumor antigens and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results